Reports
Reports
Sale
The global adrenal crisis treatment market attained a value of USD 5.56 million in 2021. The market is estimated to grow at a CAGR of 5.48% and is expected to reach a value of USD 8.99 million by 2030. The market growth is expected to be driven by increased awareness about the importance of early diagnosis of congenital disorders.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
An adrenal crisis occurs when your adrenal glands do not produce enough of the hormone cortisol. It is a potentially fatal complication of adrenal insufficiency (Addison's disease). The adrenal glands are small and triangle-shaped and located just above each kidney. They produce hormones such as cortisol. Cortisol has an impact on nearly every organ and tissue in the body, some of its functions are as follows:
A lack of blood flow may result from an adrenal crisis (shock). Shock spreads quickly and can harm the organs. An adrenal crisis can kill up to 20% of people in shock, if not treated. Other threatening symptoms include seizures or coma.
The following are the most common symptoms of an adrenal crisis:
According to the global adrenal crisis treatment market research report, the market can be categorised into the following segments:
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Market Break Up by Indication
Market Break Up by Diagnosis Method
Market Break Up by Treatment Method
Market by Treatment Channel
Market Break up Region
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Adrenaline crises are uncommon, about 42% of people with adrenal insufficiency will experience an adrenal crisis. Adrenal insufficiencies affect 1 in every 100,000 people in the United States.
Globally, primary adrenal insufficiency is estimated to affect 82-144 people per million, with autoimmunity being the most common cause in adults and genetic causes, particularly enzyme defects, being the most common cause in children. Secondary adrenal deficiency is estimated to affect 150-280 people per million. The most common cause is believed to be corticosteroid-induced insufficiency, even though the incidence of clinically relevant deficiency after glucocorticoid discontinuation is widely debated.
Increased awareness about the importance of early diagnosis of congenital disorders is expected to drive the adrenal insufficiency treatment market during the forecast period. Acquired adrenal insufficiency is expected to grow at a faster rate during the forecast period due to an increase in the risk of trauma cases caused by a variety of factors, such as road injuries, war-related trauma, other accidents, and an increase in global disease burden.
Because of drug treatment efficiency, there is a growing global demand for the development of newer and more technologically advanced products. As a result, major market players are investing in research and development programmes to develop new drugs.
Improving healthcare infrastructure, rising awareness about the importance of timely diagnosis of underlying disorders such as adrenal insufficiency, and a large patient population are expected to present significant opportunities for the Asia Pacific adrenal crisis treatment market in the near future. Increased public and private healthcare spending in China and India are expected to attract manufacturers to these markets.
At present, patients with adrenal insufficiency are given oral glucocorticoid replacement treatment, which does not exactly match the normal physiologic cortisol rhythm. Another novel method for treating adrenal insufficiency is continuous subcutaneous hydrocortisone infusion therapy, which is delivered via an insulin pump. During the forecast period, all of these factors are expected to drive the adrenal insufficiency market.
The report gives an in-depth analysis of the key players involved in the global market, sponsors manufacturing the therapies, and putting them through trials to get FDA approvals. The companies included in the market are as follows:
REPORT FEATURES | DETAILS |
Base Year | 2023 |
Historical Period | 2017-2023 |
Forecast Period | 2024-2032 |
Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
Breakup by Indication |
|
Breakup by Diagnosis Method |
|
Breakup by Treatment Method |
|
Breakup by Treatment Channel |
|
Breakup by Region |
|
Market Dynamics |
|
Supplier Landscape |
|
Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
2 Research Methodology
3 Executive Summary
4 Adrenal Crisis Treatment Overview
4.1 Guidelines and Stages
4.2 Pathophysiology
4.3 Screening and Diagnosis
4.4 Treatment Pathway
5 Patient Profile
5.1 Patient Profile Overview
5.2 Patient Psychology and Emotional Impact Factors
5.3 Risk Assessment and Treatment Success Rate
6 Current Scenario Evaluation and Regulatory Framework
6.1 Emerging Therapies and Clinical Trials Synopsis
6.2 Patent Landscape
6.2.1 Patent Overview
6.2.1.1 Patent Status and Expiry
6.2.1.2 Timelines from Drug Development to Commercial Launch
6.2.1.3 New Drug Application
6.2.1.3.1 Documentation and Approval Process
6.3 Cost of Treatment
6.4 Regulatory Framework
6.4.1 Regulatory Overview
6.4.1.1 US FDA
6.4.1.2 EU EMA
6.4.1.3 INDIA CDSCO
6.4.1.4 JAPAN PMDA
6.4.1.5 Others
7 Challenges and Unmet Needs
7.1 Treatment Pathway Challenges
7.2 Compliance and Drop-out Analysis
7.3 Awareness and Prevention Gaps
8 Global Adrenal Crisis Treatment Market
8.1 Global Adrenal Crisis Treatment Market Overview
8.2 Global Adrenal Crisis Treatment Market Analysis
8.2.1 Market Overview
8.2.1.1 Global Historical Adrenal Crisis Treatment Market Value (2017-2023)
8.2.1.2 Global Forecast Adrenal Crisis Treatment Market Value (2024-2032)
8.2.2 Global Adrenal Crisis Treatment Market by Indication
8.2.2.1 Market Overview
8.2.2.1.1 Primary
8.2.2.1.2 Secondary
8.2.2.1.3 Tertiary
8.2.3 Global Adrenal Crisis Treatment Market by Diagnosis Method
8.2.3.1 Market Overview
8.2.3.1.1 Blood Test
8.2.3.1.2 ACTH Stimulation Test
8.2.3.1.3 Insulin-Induced Hypoglycemia Test
8.2.3.1.4 Imaging Tests
8.2.4 Global Adrenal Crisis Treatment Market by Treatment Method
8.2.4.1 Market Overview
8.2.4.1.1 Oral Corticosteroids
8.2.4.1.1.1 Hydrocortisone
8.2.4.1.1.2 Fludrocortisone acetate
8.2.4.1.2 Intravenous Injections
8.2.4.1.2.1 Corticosteroids
8.2.4.1.2.2 Saline Solution
8.2.4.1.2.3 Sugar (dextrose)
8.3 Global Adrenal Crisis Treatment Market by Treatment Channel
8.3.1 Public
8.3.2 Private
8.4 Global Adrenal Crisis Treatment Market by Region
8.4.1 Market Overview
8.4.1.1 North America
8.4.1.2 Europe
8.4.1.3 Asia Pacific
8.4.1.4 Latin America
8.4.1.5 Middle East and Africa
9 North America Adrenal Crisis Treatment Market
9.1 Market Share by Country
9.2 United States of America
9.2.1 Historical Trend (2017-2023)
9.2.2 Forecast Trend (2024-2032)
9.3 Canada
9.3.1 Historical Trend (2017-2023)
9.3.2 Forecast Trend (2024-2032)
10 Europe Adrenal Crisis Treatment Market
10.1 Market Share by Country
10.2 United Kingdom
10.2.1 Historical Trend (2017-2023)
10.2.2 Forecast Trend (2024-2032)
10.3 Germany
10.3.1 Historical Trend (2017-2023)
10.3.2 Forecast Trend (2024-2032)
10.4 France
10.4.1 Historical Trend (2017-2023)
10.4.2 Forecast Trend (2024-2032)
10.5 Italy
10.5.1 Historical Trend (2017-2023)
10.5.2 Forecast Trend (2024-2032)
10.6 Others
11 Asia Pacific Adrenal Crisis Treatment Market
11.1 Market Share by Country
11.2 China
11.2.1 Historical Trend (2017-2023)
11.2.2 Forecast Trend (2024-2032)
11.3 Japan
11.3.1 Historical Trend (2017-2023)
11.3.2 Forecast Trend (2024-2032)
11.4 India
11.4.1 Historical Trend (2017-2023)
11.4.2 Forecast Trend (2024-2032)
11.5 ASEAN
11.5.1 Historical Trend (2017-2023)
11.5.2 Forecast Trend (2024-2032)
11.6 Australia
11.6.1 Historical Trend (2017-2023)
11.6.2 Forecast Trend (2024-2032)
11.7 Others
12 Latin America Adrenal Crisis Treatment Market
12.1 Market Share by Country
12.2 Brazil
12.2.1 Historical Trend (2017-2023)
12.2.2 Forecast Trend (2024-2032)
12.3 Argentina
12.3.1 Historical Trend (2017-2023)
12.3.2 Forecast Trend (2024-2032)
12.4 Mexico
12.4.1 Historical Trend (2017-2023)
12.4.2 Forecast Trend (2024-2032)
12.5 Others
13 Middle East and Africa Adrenal Crisis Treatment Market
13.1 Market Share by Country
13.2 Saudi Arabia
13.2.1 Historical Trend (2017-2023)
13.2.2 Forecast Trend (2024-2032)
13.3 United Arab Emirates
13.3.1 Historical Trend (2017-2023)
13.3.2 Forecast Trend (2024-2032)
13.4 Nigeria
13.4.1 Historical Trend (2017-2023)
13.4.2 Forecast Trend (2024-2032)
13.5 South Africa
13.5.1 Historical Trend (2017-2023)
13.5.2 Forecast Trend (2024-2032)
13.6 Others
14 Global Adrenal Crisis Market Dynamics
14.1 Market Drivers and Constraints
14.2 SWOT Analysis
14.3 Porter’s Five Forces Model
14.4 Key Demand Indicators
14.5 Key Price Indicators
14.6 Industry Events, Initiatives, and Trends
14.7 Value Chain Analysis
15 Global Adrenal Crisis Treatment Market Supplier Landscape
15.1 Takeda Pharmaceutical Company Limited
15.1.1 Company Overview
15.1.2 Product Portfolio
15.1.3 Demographic Reach and Achievements
15.1.4 Mergers and Acquisitions
15.1.5 Certifications
15.2 Sandoz International GmbH
15.2.1 Company Overview
15.2.2 Product Portfolio
15.2.3 Demographic Reach and Achievements
15.2.4 Mergers and Acquisitions
15.2.5 Certifications
15.3 Pfizer Inc
15.3.1 Company Overview
15.3.2 Product Portfolio
15.3.3 Demographic Reach and Achievements
15.3.4 Mergers and Acquisitions
15.3.5 Certifications
15.4 Bristol-Myers Squibb Company
15.4.1 Company Overview
15.4.2 Product Portfolio
15.4.3 Demographic Reach and Achievements
15.4.4 Mergers and Acquisitions
15.4.5 Certifications
15.5 Merck KGaA
15.5.1 Company Overview
15.5.2 Product Portfolio
15.5.3 Demographic Reach and Achievements
15.5.4 Mergers and Acquisitions
15.5.5 Certifications
15.6 Antares Pharma
15.6.1 Company Overview
15.6.2 Product Portfolio
15.6.3 Demographic Reach and Achievements
15.6.4 Mergers and Acquisitions
15.6.5 Certifications
15.7 Mallinckrodt Pharmaceuticals
15.7.1 Company Overview
15.7.2 Product Portfolio
15.7.3 Demographic Reach and Achievements
15.7.4 Mergers and Acquisitions
15.7.5 Certifications
15.8 Mylan Pharmaceutical AG
15.8.1 Company Overview
15.8.2 Product Portfolio
15.8.3 Demographic Reach and Achievements
15.8.4 Mergers and Acquisitions
15.8.5 Certifications
15.9 eTon Pharmaceuticals
15.9.1 Company Overview
15.9.2 Product Portfolio
15.9.3 Demographic Reach and Achievements
15.9.4 Mergers and Acquisitions
15.9.5 Certifications
16 Global Adrenal Crisis Treatment Distribution Model (Additional Insight)
16.1 Overview
16.2 Potential Distributors
16.3 Key Parameters for Distribution Partner Assessment
17 Payment Methods (Additional Insight)
17.1 Government Funded
17.2 Private Insurance
17.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
The market growth is expected to be driven by increased awareness about the importance of early diagnosis of congenital disorders.
Poor reimbursement, high treatment costs, and various drug side effects may restrict the market growth.
The market was estimated to reach about a value of USD 5.56 million in 2021.
The market is expected to grow at a CAGR of 5.48% during the forecast period of 2024-2032.
The market is likely to attain a value of USD 8.99 million by 2030.
The regions involved in this market are North America, Latin America, Asia Pacific, Europe, and Latin America.
In the event of an adrenal crisis, an intravenous or intramuscular injection of hydrocortisone (an injectable corticosteroid) must be administered right away.
ACTH Stimulation Analysis is the most accurate test for determining adrenal insufficiency.
The key companies involved in the market are Takeda Pharmaceutical Company Limited, Sandoz International GmbH, Pfizer Inc, Bristol-Myers Squibb Company, Merck KGaA, Antares Pharma, Mallinckrodt Pharmaceuticals, Mylan Pharmaceutical AG, and eTon Pharmaceuticals, among others.
Mini Report
Single User License
Five User License
Corporate License
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.